MedTrace Logo

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

NCT02341014 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-04-04

Study results available
· View outcomes & findings →

Summary

This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.

Conditions

  • T-cell Lymphomas
  • Relapsed or Refractory

Interventions

DRUG

Carfilzomib

The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .

DRUG

Romidepsin

DRUG

Lenalidomide

Sponsors & Collaborators

Principal Investigators

  • Steven Horwitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-02
Primary Completion
2023-01-11
Completion
2023-01-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341014 on ClinicalTrials.gov